Alzamend Neuro is trading 6.3% lower at $1.45, coinciding with biotech-sector weakness rather than a company-specific announcement. - Biotech ETF XBI was down 5.19% in regular trading; the broader indices supplied were higher. - No company-specific announcement for November 6 appeared in the company’s press-release listing; its latest listed releases were dated September 16. - Trading volume was not provided.